logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Scopio Raises $50M To Take A Deeper Look Into Our Blood Cells

Feb 09, 2022•almost 4 years ago

Amount Raised

$50 Million

Tel Aviv

Description

Scopio Labs, provider of the world's first full-field digital cell morphology solution, today announced a $50M investment for its end-to-end hardware and software platform for digitizing, quantifying and analyzing hematology and other digital cytology samples. The Series C round included OurCrowd, Aurum Ventures, Mizrahi-Tefahot Bank Invest and Ilex Medical, with the participation of strategic investors operating in the field and existing investors.

Company Information

Company

Scopio Labs

Location

Tel Aviv, Tel-Aviv District, Israel

About

Scopio Labs is transforming cell morphology analysis, offering a suite of fully digital diagnostic applications and platforms that drastically enhance clinical workflows and enable faster, earlier, and more accurate detection and diagnosis of disease, expediting patients' access to life-saving treatments. Solving the tradeoff between field-of-view and resolution, Scopio enables labs to assess and analyze cell morphology at unprecedented scale and depth. The company's combination of high-resolution imaging and an AI-powered decision support system makes the diagnosis process more efficient and consistent across the continuum of care. Scopio Labs' FDA-cleared, CE-marked Full-Field Peripheral Blood Smear application and its ScopioVet veterinary application are in full commercial use across the U.S. and Europe.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech